The success of Sildenafil initially sparked a surge for the drug industry, but recent shifts present a complicated scenario for investors. Lower-cost alternatives are eroding revenue, and ongoing litigation add further https://honeyqmri137805.ltfblog.com/39647651/sildenafil-and-big-pharma-a-risky-play